“Made in China 2025” initiative, nearing Beijing’s target, threatens U.S. U.S. Senator Marco Rubio (R-FL) September 10, 2024 Washington Post …[I]n May 2015, Beijing went public with a 10-year plan to dominate high-value, high-technology sectors…. [W]ith the decade...
U.S. Senator Marco Rubio (R-FL) released a report titled “The World China Made: ‘Made in China 2025’ Nine Years Later,” which reviews the successes and failures of Communist China’s “Made in China 2025” industrial policy. It is the sequel to Rubio’s 2019 report titled...
U.S. Senator Marco Rubio’s (R-FL) office will host in-person Mobile Office Hours next week to assist constituents with federal casework issues in their respective local communities. These office hours offer constituents who do not live close to one of Senator Rubio’s...
Biden-Harris Economy Is Leaving Men Behind U.S. Senator Marco Rubio (R-FL) September 6, 2024 Fox News Hidden in the shadows and forgotten: That’s the only way to describe the state of male employment in this country. The percentage of men aged 25-54 who report working...
Recently, the Biden-Harris Administration implemented an expansion of nonimmigrant visas (NIV) to Cubans. Allowing the Cuban regime to benefit from visas is yet another move this administration has made to appease the Cuban dictatorship. This also puts our nation at...
Yesterday, the Brazilian Supreme Court upheld the decision to ban Brazilians from access to social media platform X, formerly known as Twitter. This countrywide ban raises concerns of freedom of speech and judicial overreach in Brazil. U.S. Senator Marco Rubio (R-FL)...
Washington, D.C. — U.S. Senators Marco Rubio (R-FL), Rick Scott (R-FL), Josh Hawley (R-MO), Ron Johnson (R-WI), Mike Braun (R-IN), Kevin Cramer (R-ND), Cindy Hyde-Smith (R-MS) and Dan Sullivan (R-AK) sent a letter to the president and CEO of Pharmaceutical Research and Manufacturers of America (PhRMA) asking that they provide solutions to address the rising cost of prescription drugs.
The full text of the letter is below.
Dear Mr. Ubl,
We hear it every day in our states. Drug prices are too high. Patients are paying more and more every year for life-saving drugs, and some are forced to go without those treatments because they simply cannot afford them.
Soaring drug prices are a serious problem and a problem Washington should have addressed long ago. We cannot understand why Americans pay two to six times more than the rest of the world for brand name prescription drugs or why the U.S. comprised 42% of global pharmaceutical revenues based on 2016 data. American consumers should not be subsidizing European countries so they can keep prices low for their consumers. The system needs to change.
Transparency in health care costs is key to giving patients flexibility and control over their health care decisions. American consumers should always come first, and it is time for U.S. companies to be more transparent and bring down the prices of prescription drugs for Americans relative to Canada, Europe and other developed nations.
We write today to ask, as the trade association representing the pharmaceutical industry, what solutions does your association have that would increase transparency and directly lower the list price of drugs for consumers? What specific plans do you have to address price disparities in the international market? And are you willing to work with us to find real solutions to help the American people?
In Washington, there is often too much finger pointing and not enough problem solving. We do not accept that. We are working to find solutions that directly help patients get the health care they deserve. Thank you in advance for your response. We look forward to your cooperation as we work together to lower the cost of prescription drugs.
Sincerely,